NCT04848506Phase 2, phase 3Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Study sponsor: Cytokinetics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03Estimated
Enrollment · participants900Estimated
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years. After: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of serious adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Serious Adverse Events (SAEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported LVEF \<50% Time frame: Baseline to End of study, up to 5 years.

Primary completion date changed

Before: Mar 2028. After: Mar 2029.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview